Our ESG Approach
Nxera Pharma has worked hard to lay the foundations of our ESG commitment and to build a clear roadmap to achieving our ESG goals.
At our inaugural ESG Committee meeting in October 2022, Nxera Pharma worked to build our ESG roadmap and identify potential key priority issues (Materiality) and corresponding key performance indicators (KPIs).
The Materiality and KPIs identified by the ESG Committee were approved by our Board of Directors in March 2023. As Nxera’s ESG long journey roadmap, the Materiality and KPIs set out below are our ESG priority issues and goals that our organization will strive to achieve in the coming years. The objective of our ESG Committee is to implement these ESG goals across our organization and to collaborate with both internal and external stakeholders to ensure these priorities become the foundation of our culture, value and business operations. We recognize that our Materiality and KPIs are long-term objectives that we hope will shape our organization’s values and we look forward to reporting progress through annual ESG reports
CEO Message
Dear Stakeholders
At Nxera Pharma, we are fully committed to realizing a sustainable future through supporting breakthroughs in medicine. Through our work, our goal is to improve the quality of life and health of people around the world. We practice world-leading science to create life-changing medicines.
Following the establishment of our ESG Committee in 2022, we have worked to assess our organization’s current ESG practices, identify ESG priorities and action our most important initiatives.
We are focused on embedding ESG practices into our business operations and in our culture and behaviors.
I am very proud of the progress we have made across all four of our KPIs since the formation of our ESG committee, evident in this report. However, there is still more to do, particularly as our global organization has nearly doubled in size in 2023 following the addition of Idorsia Pharmaceuticals Japan –currently Nxera Pharma Japan (“NPJ”) – and Idorsia Pharmaceuticals Korea– currently Nxera Pharma Korea (“NPK”), bringing a new dimension to our business. This new stage of our development motivates us even more to continuing our efforts and driving forward our ESG initiatives in 2024 and beyond.
Chris Cargill
Representative Executive Officer, President & CEO
Nxera Pharma